Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus (Q40432502)

20 September 2017

title

Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus (English)

1 reference

20 September 2017

0 references

0 references

6

1 reference

20 September 2017

5

Guus F Rimmelzwaan

1 reference

20 September 2017

4

Geert van Amerongen

1 reference

20 September 2017

Petra B. van den Doel

series ordinal

3

object named as

Petra van den Doel

1 reference

20 September 2017

Byron E Martina

1

1 reference

20 September 2017

Penelopie Koraka

series ordinal

2

1 reference

20 September 2017

language of work or name

English

0 references

publication date

20 November 2007

1 reference

20 September 2017

1 reference

20 September 2017

volume

26

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

153-157

1 reference

Exotic and emerging viral encephalitides

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Recent advances in Japanese encephalitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

A case of fatal West Nile virus meningoencephalitis associated with receipt of blood transfusions after open heart surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

West Nile virus infection transmitted by blood transfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Transmission of West Nile Virus through Blood Transfusion in the United States in 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

West Nile virus encephalitis in a kidney transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Movement disorders in Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Persistent movement disorders following Japanese encephalitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Japanese encephalitis: development of new candidate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Protection against Japanese encephalitis by inactivated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Crystal Structure of the West Nile Virus Envelope Glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Structural basis of West Nile virus neutralization by a therapeutic antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Tick-borne encephalitis virus envelope protein E-specific monoclonal antibodies for the study of low pH-induced conformational changes and immature virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Neutralizing peptide ligands selected from phage-displayed libraries mimic the conformational epitope on domain III of the Japanese encephalitis virus envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Epitope model of tick-borne encephalitis virus envelope glycoprotein E: analysis of structural properties, role of carbohydrate side chain, and conformational changes occurring at acidic pH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

A ligand-binding pocket in the dengue virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Antigenic structure of flavivirus proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.055

From the Centers for Disease Control and Prevention. Possible West Nile virus transmission to an infant through breast-feeding--Michigan, 2002

7 January 2021

1 reference

12 December 2020

Possible West Nile virus transmission to an infant through breast-feeding--Michigan, 2002.

1 reference

12 December 2020

The flavivirus envelope protein E: isolation of a soluble form from tick-borne encephalitis virus and its crystallization

1 reference

12 December 2020

Vaccines for preventing Japanese encephalitis

1 reference

12 December 2020

10.1016/J.VACCINE.2007.10.055

Identifiers

DOI

1 reference

20 September 2017

1 reference